

Attorney Docket No. 21415-0014

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Ranjeny THOMAS et al.	Confirmation No. 1436
Appl. No.:	10/524,539	Examiner: Unassigned
Filing Date:	February 14, 2005	Art Unit: Unassigned
Title:	IMMUNOMODULATING COMPOSITIONS, PROCESSES FOR THEIR PRODUCTION AND USES THEREFOR	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

RELEVANCE

These documents came to the Applicants' attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

September 12, 2005
Date



HELLER EHRMAN LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036
Phone: 202-912-2000
Fax: 202-912-2020

Paul M. Booth
Reg. No. 40,244

Customer No. 26633

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/524,539
		Filing Date	February 14, 2005
		First Named Inventor	Ranjeny THOMAS et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	21415-0014US	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A01	SHEILA CALDWELL et al., "Mechanisms of Ganglioside Inhibition of APC Function", The Journal of Immunology, 2003, pp. 1676-1683	
	A02	NICK GIANNOUKAKIS et al., "Prolongation of Cardiac Allograft Survival Using Dendritic Cells Treated with NF-KB Decoy Oligodeoxyribonucleotides", Molecular Therapy, May 2000, pp. 430-437, Vol. 1, No. 5	
	A03	BRADFORD L. MCRAE et al., "Interferon-α and -β inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14+ precursors", Blood, July 2000, pp. 210-217, Vol. 96, No. 1	
	A04	BRENDAN JOHN O'SULLIVAN et al., "CD40 Ligation Conditions Dendritic Cell Antigen-Presenting Function Through Sustained Activation of NF-kB", The Journal of Immunology, 2002, pp. 5491-5498	
	A05	JIANPING PAN et al., "Dexamethasone inhibits the antigen presentation of dendritic cells in MHC class II pathway", Immunology Letters, 2001, pp. 153-161, Vol. 76	
	A06	CARL E. RUBY et al., "2,3,7,8-Tetrachlorodibenzo-p-dioxin Suppresses Tumor Necrosis Factor-α and Anti-CD40-Induced Activation of NF-kB/Rel in Dendritic Cells: p50 Homodimer Activation is not Affected", Molecular Pharmacology, 2002, pp. 722-728, Vol. 62, No. 3	
	A07	VALERIE VERHASSELT et al., "N-Acetyl-L-Cysteine Inhibits Primary Human T Cell Responses at the Dendritic Cell Level: Association with NF-kB Inhibition", The American Association of Immunologists, 1999, pp. 2569-2574	
	A08	SATOMICHI YOSHIMURA et al., "Effective antigen presentation by dendritic cells is NF-kB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines", International Immunology, 2001, pp. 675-683, Vol. 13, No. 5	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.